Tower Research Capital LLC TRC Purchases 65,112 Shares of Inovio Pharmaceuticals, Inc. (NASDAQ:INO)

Tower Research Capital LLC TRC increased its position in shares of Inovio Pharmaceuticals, Inc. (NASDAQ:INO – Get Rating) by 101.8% in the 3rd quarter, according to the company in its most recent 13F filing with the Securities & Exchange Commission. The institutional investor owned 129,084 shares of the biopharmaceutical company’s stock after acquiring an additional 65,112 shares during the quarter. Tower Research Capital LLC TRC owned about 0.05% of Inovio Pharmaceuticals worth $222,000 as of its most recent SEC filing.

Other hedge funds have also bought and sold shares of the company. TIAA FSB purchased a new position in Inovio Pharmaceuticals in the 2nd quarter worth $25,000. Great West Life Assurance Co. Can purchased a new position in shares of Inovio Pharmaceuticals in the third quarter worth about $28,000. Keebeck Alpha LP acquired a new stake in shares of Inovio Pharmaceuticals during the second quarter worth about $29,000. Eqis Capital Management Inc. boosted its position in Inovio Pharmaceuticals by 28.3% in the second quarter. Eqis Capital Management Inc. now owns 29,987 shares of the biopharmaceutical company’s stock valued at $52,000 after buying an additional 6,613 shares during the last quarter. Finally, Amalgamated Bank boosted its position in Inovio Pharmaceuticals by 17.5% in the third quarter. Amalgamated Bank now owns 31,932 shares of the biopharmaceutical company’s stock valued at $55,000 after buying an additional 4,759 shares during the last quarter. Institutional investors and hedge funds own 46.44% of the company’s stock.

Analysts Set New Price Targets

INO has been the subject of a number of recent research reports. Maxim Group lowered shares of Inovio Pharmaceuticals from a “buy” rating to a “hold” rating in a research report on Wednesday, November 9th. StockNews.com raised Inovio Pharmaceuticals from a “sell” rating to a “hold” rating in a report on Monday, December 19th. Finally, Royal Bank of Canada decreased their target price on shares of Inovio Pharmaceuticals from $3.00 to $2.00 and set a “sector perform” rating for the company in a research note on Thursday. One equities research analyst has rated the stock with a sell rating and five have given a hold rating to the stock. According to MarketBeat.com, Inovio Pharmaceuticals has a consensus rating of “Hold” and a consensus target price of $2.33.

Inovio Pharmaceuticals Trading Up 1.5 %

Shares of NASDAQ:INO opened at $1.32 on Monday. The firm has a market capitalization of $343.37 million, a price-to-earnings ratio of -1.12 and a beta of 1.09. The business’s 50 day moving average price is $1.59 and its 200-day moving average price is $1.84. The company has a debt-to-equity ratio of 0.07, a current ratio of 3.25 and a quick ratio of 3.69. Inovio Pharmaceuticals, Inc. has a 1 year low of $1.19 and a 1 year high of $4.00.

Inovio Pharmaceuticals (NASDAQ:INO – Get Rating) last released its earnings results on Wednesday, March 1st. The biopharmaceutical company reported ($0.22) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($0.16) by ($0.06). The business had revenue of $0.13 million for the quarter, compared to analysts’ expectations of $0.46 million. Inovio Pharmaceuticals had a negative return on equity of 98.03% and a negative net margin of 2,726.74%. During the same period in the previous year, the company earned ($0.50) EPS. On average, equities research analysts forecast that Inovio Pharmaceuticals, Inc. will post -0.59 earnings per share for the current fiscal year.

Inovio Pharmaceuticals Profile

(Get Rating)

Inovio Pharmaceuticals, Inc engages in the provision of designed DNA medicines to treat and protect people from infectious diseases, cancer, and diseases associated with human papillomavirus. Its product pipeline includes VGX-3100, INO-3107, INO-5410, INO-4800, and PENNVAX-GP. The company was founded by David B.